Safety and Efficacy of Sofosbuvir/Velpatasvir in a Genotype 1-3 HCV Infected Russian and Swedish Population: Results from a Phase 3, Prospective Trial

被引：0
|
作者：
Weiland, Ola [1 ]
Zhdanov, Konstantin [2 ]
Chulanov, Vladimir P. [3 ]
McNabb, Brian L. [4 ]
Lu, Sophia [5 ]
Svarovskaia, Evguenia S. [6 ]
McNally, John [4 ]
Brainard, Diana M. [4 ]
Subramanian, Mani [4 ]
Abdurakhmanov, Dzhamal [7 ]
Isakov, Vasily [8 ]
机构：
[1] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Infect Dis, Dept Med, Stockholm, Sweden
[2] Mil Med Acad, Dept Infect Dis, St Petersburg, Russia
[3] Cent Res Inst Epidemiol, Clin Diagnost & Res Ctr, Moscow, Russia
[4] Gilead Sci Inc, Clin Res, 353 Lakeside Dr, Foster City, CA 94404 USA
[5] Gilead Sci Inc, Biostat, 353 Lakeside Dr, Foster City, CA 94404 USA
[6] Gilead Sci Inc, Virol, 353 Lakeside Dr, Foster City, CA 94404 USA
[7] Sechenov First Moscow State Univ, Moscow, Russia
[8] Fed Res Ctr Nutr Biotechnol & Food Safety, Dept Gastroenterol & Hepatol, Moscow, Russia
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1186
引用
收藏
页码：639A / 639A
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study
    Heo, Jeong
    Kim, Yoon Jun
    Lee, Sung Wook
    Lee, Youn-Jae
    Yoon, Ki Tae
    Byun, Kwan Soo
    Jung, Yong Jin
    Tak, Won Young
    Jeong, Sook-Hyang
    Kwon, Kyung Min
    Suri, Vithika
    Wu, Peiwen
    Jang, Byoung Kuk
    Lee, Byung Seok
    Cho, Ju-Yeon
    Jang, Jeong Won
    Yang, Soo Hyun
    Paik, Seung Woon
    Kim, Hyung Joon
    Kwon, Jung Hyun
    Park, Neung Hwa
    Kim, Ju Hyun
    Kim, In Hee
    Ahn, Sang Hoon
    Lim, Young-Suk
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (04): : 504 - +
  • [22] Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort
    Wong, Yu Jun
    Thurairajah, Prem Harichander
    Kumar, Rahul
    Tan, Jessica
    Fock, Kwong Ming
    Law, Ngai Moh
    Li, Weiquan
    Kwek, Andrew
    Tan, Yu Bin
    Koh, Jingyun
    Lee, Zheng Cong
    Kumar, Loshini Senthil
    Teo, Eng Kiong
    Ang, Tiing-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (05) : 1300 - 1308
  • [23] Safety and Efficacy of Coblopasvir and Sofosbuvir in Genotype 1, 2, 3, and 6 HCV-Infected Patients with Compensated Cirrhosis or without Cirrhosis
    Rao, Huiying
    Song, Guangjun
    Li, Guangming
    Yang, Yongfeng
    Wu, Xiaofeng
    Guan, Yujuan
    Mao, Qing
    Jiang, Xiangjun
    Wang, Changyuan
    Zhang, Ying
    Zhang, Ying
    Jia, Jidong
    Guo, Xiaolin
    Zheng, Sujun
    Li, Chenghao
    Ning, Jing
    Qin, Hong
    Pan, Hai
    Wei, Lai
    HEPATOLOGY, 2018, 68 : 582A - 583A
  • [24] EFFICACY AND SAFETY OF ADDING RIBAVIRIN FOR GENOTYPE 3 HCV COMPENSATED CIRRHOSIS RECEIVING 12-WEEKS OF SOFOSBUVIR/VELPATASVIR: A META-ANALYSIS
    Loo, Jing Hong
    Xu, Wen Xin Flora
    Low, Gerald J.
    Tay, Wei Xuan
    Ang, Le Shaun
    Tam, Yew Chong
    Kumar, Rahul
    Wong, Yu Jun
    GASTROENTEROLOGY, 2022, 162 (07) : S1281 - S1281
  • [25] Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: An Integrated Analysis of Phase 2 and Phase 3 Clinical Trials
    Roberts, Stuart Keith
    Buti, Maria
    Foster, Graham R.
    Luis Calleja, Jose
    Sood, Ajit
    Isakov, Vasily A.
    Ola, R.
    Weiland, Hj
    Stamm, Luisa
    Ni, Liyun
    Svarovskaia, Evguenia
    Brainard, Diana
    Wyles, David L.
    Antonio Pineda, Juan
    Thompson, Alexander
    Esteban, Rafael
    Mangia, Alessandra
    HEPATOLOGY, 2018, 68 : 373A - 374A
  • [26] Safety and efficacy of velpatasvir and sofosbuvir with or without ribavirin for the treatment of HCV genotypes 1-6: results of the HCV-TARGET Study
    Khalili, M.
    Welzel, T. M.
    Lim, J. K.
    Lutchman, G. A.
    Nelson, D. R.
    Borg, B.
    Lok, A. S.
    Ramani, A.
    Reau, N.
    Vainorius, M.
    Fried, M. W.
    Landis, C. S.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S716 - S717
  • [27] RESISTANCE ANALYSIS OF GENOTYPE 1 OR 3 HCV-INFECTED PATIENTS TREATED WITH SOFOSBUVIR/VELPATASVIR+GS-9857 FOR 6 OR 8 WEEKS
    Gane, E.
    Svarovskaia, E. S.
    Dvory-Sobol, H.
    Hyland, R. H.
    Stamm, L. M.
    Brainard, D. M.
    Miller, M. D.
    Mo, H.
    Schwabe, C.
    Stedman, C. A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S401 - S402
  • [28] A Randomized, Controlled, Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir or Sofosbuvir/Velpatasvir for 12 Weeks in Direct Acting Antiviral-Experienced Patients with Genotype 1-6 HCV Infection: The POLARIS-4 Study
    Zeuzem, Stefan
    Flamm, Steven L.
    Tong, Myron J.
    Vierling, John M.
    Pianko, Stephen
    Buggisch, Peter
    de Ledinghen, Victor
    Hyland, Robert H.
    Wu, Xiaoru
    Svarovskaia, Evguenia S.
    Stamm, Luisa M.
    Brainard, Diana M.
    Subramanian, Mani
    McHutchison, John G.
    Verna, Elizabeth C.
    Bansal, Meena B.
    Landis, Charles S.
    Strasser, Simone I.
    Cooper, Curtis
    Kowdley, Kris V.
    HEPATOLOGY, 2016, 64 : 59A - 59A
  • [29] EXPOSURE-RESPONSE RELATIONSHIPS FOR SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR IN HCV-INFECTED PATIENTS IN PHASE III STUDIES.
    Kirby, B. J.
    Stamm, L. M.
    Ni, L.
    Mathias, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S41 - S41
  • [30] Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients
    Margusino-Framinan, Luis
    Cid-Silva, Purificacion
    Rotea-Salvo, Sandra
    Mena-de-Cea, Alvaro
    Suarez-Lopez, Francisco
    Vazquez-Rodriguez, Pilar
    Delgado-Blanco, Manuel
    Sanclaudio-Luhia, Ana Isabel
    Martin-Herranz, Isabel
    Castro-Iglesias, Angeles
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (E1) : E41 - E47
12345